Citius Pharmaceuticals Completes Merger of Subsidiary with TenX Keane to form Citius Oncology, Inc.
Citius Pharma(CTXR) Prnewswire·2024-08-13 04:22LYMPHIR™ for the treatment of cutaneous T-cell lymphoma approved by the FDACitius Pharmaceuticals, Inc. holds approximately 90% of publicly traded Citius Oncology, Inc.Shares of Citius Oncology, Inc. anticipated to begin trading on Nasdaq under the ticker "CTOR" on August 13, 2024 CRANFORD, N.J., Aug. 12, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-cl ...